Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. Issue 1 (January 2022)

• Record Type: Journal Article
• Authors: Colombo, Nicoletta; Dubot, Coraline; Lorusso, Domenica; Caceres, M. Valeria; Hasegawa, Kosei; Shapira-Frommer, Ronnie; Tewari, Krishnansu S.; Salman, Pamela; Usta, Edwin Hoyos; Yañez, Eduardo; Gümüş, Mahmut; Olivera Hurtado de Mendoza, Mivael; Samouëlian, Vanessa; Castonguay, Vincent; Arkhipov, Alexander; Toker, Sarper; Li, Kan; Keefe, Stephen M.; Monk, Bradley J.
• Is Part Of: Obstetrical & gynecological survey. Volume 77:Issue 1(2022)
• Page Start: 30
• Page End: 31
• Publication Date: 2022-01
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; Generative organs, Female -- Surgery -- Periodicals; 618
• DOI: 10.1097/01.ogx.0000805152.09501.f1
• Languages: English
• ISSNs: 0029-7828

Abstract

Abstract : (Abstracted from N Engl J Med 2021;385:1856–1867) Platinum-based chemotherapy plus bevacizumab and paclitaxel is the standard first-line therapy for persistent, recurrent, or metastatic cervical cancer. The phase 2 KEYNOTE-158 trial found evidence of a response to pembrolizumab among patients with programmed death ligand-1 (PD-L1) positive cervical cancer.